The case for & against
Bull & Bear analysis
Bearish
NewAmsterdam Pharma (NASDAQ: NADA) is an emerging biotechnology company focused on developing lipid-modifying therapies, particularly targeting cardiovascular risks associated with elevated lipid profiles. The company is gaining attention for its lead drug candidate, obicetrapib, which is positioned in the competitive landscape of cardiovascular therapeutics, especially in mitigating early Alzheimer's disease. NewAmsterdam's pivotal Phase 3 PREVAIL trial is a demonstration of its commitment to advancing treatment options in an essential therapeutic area, amidst increasing interest in overall cardiovascular health.
Bull says
- ↑Obicetrapib PREVAIL interim data indicates ~21% reduction in major adverse events
- ↑Analysts project 65.3% annual EPS growth; stock trades ~78% below fair value
- ↑Strong balance sheet and AI-driven trial modeling bolster operational strength
- ↑High institutional backing and positive momentum factors support upside
- ↑Dividend yield of 0.73% reflects management’s focus on shareholder returns
- ↑Regulatory tailwinds could accelerate cardiovascular therapy approvals
Bear says
- ↓Negative earnings yield and weak profitability factors signal poor return generation
- ↓High leverage raises financial risk as interest rates climb
- ↓Elevated short interest suggests potential selling pressure under bearish sentiment
- ↓PREVAIL interim readout in Q4 2026 poses a binary outcome risk
- ↓Intense competition from rival lipid-lowering therapies may limit market share
- ↓Q1 2026 loss of $48.4M on $3M revenue highlights ongoing cash burn
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 06-14-2026bullish
Transcript signals
Bull points
- observed some encouraging trends in the blinded data.
- Importantly, the year one to year two overall MACE rate has been lower than anticipated, a trend we find encouraging when viewed against historical LDL-C outcome studies in this population.
- encouraging trend.
Read full transcript analysis ›